Funding Opportunities

Please share within your networks. The estimated publication date of the funding opportunity announcement is August 5, 2021.

The National Cancer Institute (NCI) plans to publish a Funding Opportunity Announcement (FOA) as an RFA (i.e., Request for Applications) for the "Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs)” Initiative (U01).This FOA aims to support implementation science to accelerate the integration of evidence-based cancer control interventions for PLWH into HIV treatment and prevention programs worldwide by leveraging existing infrastructure. The FOA solicits applications in implementation science to address gaps in the delivery of evidence-based cancer control among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control strategies for PLWH worldwide. This Notice of Intent to Publish (NOITP) encourages multi-disciplinary teams of researchers with expertise in HIV or cancer and in implementation science to consider developing responsive applications that address the cancer control needs of PLWH populations in LMIC settings.

https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-084.html 

About Worldwide Cancer Research

We are a UK based charity funding early stage, discovery research anywhere in the world.

We have a history of recognising innovative scientific ideas that have the chance to revolutionise cancer medicine. We were founded 40 years ago to support brand new avenues of research and allow scientists to take intellectual risks in exploring challenging new concepts and approaches.

If you have a novel, exciting and creative idea that could help prevent, diagnosis or treat cancer, we may be able to support you with a project grant. Since our foundation in 1979, we have invested in nearly 2,000 research projects around the world.

Many of these projects have already improved the lives of people with cancer, and others are opening entirely new areas of cancer research. However, we know there is still so much to do, and this is where you come in.

What do we fund?

We award project grants of up to £250,000 and of 12 to 36 months in length to support basic, fundamental or translational research into the prevention, diagnosis or treatment of cancer. More information about what we fund and what we are looking for in a project can be found in our Research Strategy.

How to apply

Our 2021 grant round opens on Monday 15th February. Submission period for applications opens on Thursday 4th March and submission closes on Friday 2 April. Please visit our website for more information or contact the Research Funding team at grants@worldwidecancerresearch.org.

The NCI is pleased to announce the Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control (NOT-CA-21-033).

The purpose of this NOSI is to inform current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes. 

CGH will be hosting a webinar to address frequently asked questions about this funding opportunity on Thursday, February 25, 2021 at 9:00 a.m. EST.  Click here to join the webinar, or copy and paste the following link into your browser https://nih.zoomgov.com/j/1615455986?pwd=S2NlclFKNXlLWGs0bHV1aDlDa1BQZz09. We encourage you to share this information widely among your networks. If you have any questions about this NOSI, or the upcoming FAQ webinar, please do not hesitate to contact Elise Garton and Paul Pearlman.

Deadline: 31 March 2021

Eligibility and Eligible Individuals (Program Director/Principal Investigator):

To be eligible for an Urgent Competitive Revision or an Administrative Supplement through this NOSI and the respective FOA, applications must meet the following criteria:

• Administrative supplement applications are limited to currently funded projects supported by NCI.
• PDs/PIs must hold an active award eligible for PA-20-272 supported through NCI with sufficient time (minimum 1 year) left to complete the studies proposed after the revision/supplement has been awarded within the existing project period.
• The proposed project for supplemental funding is required to be within the scope of the parent award and be a logical extension of the original aims.
• The parent award must either already include a foreign performance site in an LMIC or the applicant must include a letter of support from an LMIC institution with the application.
• For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.

Applications are now open for the following funding schemes:

Addressing Cancer Health Disparities Through Evidence-Based Cancer Nursing Research (RE42) $100,000 - deadline May 17, 2021

• Purpose: To support oncology nursing research addressing cancer health disparities, including in the topic areas of breast, colorectal, lung or prostate cancer.

Addressing the Adverse Effects of Immunotherapy and Emerging Therapies on Cancer Patients (RE43) $150,000 - deadline May 17, 2021

• Purpose: To support oncology nursing research in symptom science addressing the adverse effects of immunotherapy and emerging therapies used in the treatment of cancer patients. Symptom Science in immunotherapy and emerging therapies has been identified as one of the top cancer nursing research priorities in need of new knowledge

Eligibility: The principal investigator must be a registered nurse actively involved in some aspect of cancer patient care, education or research and be PhD or DNSc prepared that has received and completed at least one research study of at least $50,000 as PI. Membership in ONS is not required. Open to international applicants.

For full details, visit: https://www.onfgivesback.org/funding-for-nurses/research/research-grant

Opportunity open to applicants from all countries. Please read the eligibility criteria & instructions carefully before applying: https://www.anticancerfund.org/en/evolutionary-therapy 

This Request for Application (RFA) seeks to increase clinical trial activity of evolutionarily informed therapeutic strategies aiming at improving survival outcomes of cancer patients.

Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker.

This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria).

We encourage investigators working on evolutionarily informed strategies (including adaptive therapy) to apply for funding for their clinical trial evaluating such approach in cancer patients.

For further information on what is seen as evolutionarily informed strategies and adaptive therapy, we would like to refer applicants to a recent article by Gatenby & Brown (Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 2020; 17: 675–86).

Please contact apply@anticancerfund.org for any questions related to the RFA and to check eligibility of their proposal in case of doubt.

Cancer Research UK and the US National Cancer Institute have united to define a new era in cancer research and discovery:

Cancer Grand Challenges: Dare to take on some of the most complex challenges in cancer   

Cancer Grand Challenges is a global funding platform founded by Cancer Research UK and the National Cancer Institute. Through a series of £20m ($25m) awards, Cancer Grand Challenges is giving international teams of researchers the freedom to think differently, act creatively and explore truly innovative science to take on complex questions in cancer. 

Nine new challenges to the international research community are now open for applications.
  
Call closes: 22 April 2021  

Cancer Grand Challenges news and updates – follow the team on Twitter and LinkedIn

We, the Anticancer Fund, a Belgian non-profit organization with an international scope, have joined forces with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, for a unique opportunity to support high quality clinical trials focusing on drug repurposing and therapy optimization, with special interest in the following areas:

• Rare cancers (<6/100,000)
• ‘Financial orphan’ drugs (commercially neglected drugs)
• Off patent drugs
• Prognostic and/or predictive biomarkers

We call upon all investigators to submit proposals, where funding is required to initiate a new arm of an existing multi-arm trial. Requirements include having a strong rationale with rigorous and compelling supportive data, in addition to a detailed statistical design and methodology.

Amount available for this call for proposals will be at least US$ 3 million. The amount allocated per grant will depend on the number of proposals selected for funding. Application Deadline is February 28, 2020

All information can be found here: https://www.anticancerfund.org/sites/default/files/attachments/flyer_rtfccr-acf_rfp_2020_final.pdf

Please share this information with anyone potentially interested and/or retweet to spread the news: https://twitter.com/Simple_Trials/status/1206988000418238464